OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
	478
Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study	222
A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes	168
	123
Diabetes, Obesity and Metabolism	116
Correction to “Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus”	115
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors	102
Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia	91
Issue Information	90
Long‐term adherence to glucose‐lowering medications in adults with diabetes: A data linkage study	84
Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020	78
Incidence of chronic kidney disease among adults with prediabetes in the CURE‐CKD registry, 2013–2020	78
Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis	77
The benefit of dexamethasone in patients with COVID‐19 infection is preserved in patients with diabetes	72
Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes	69
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	69
Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis	69
Global deletion of G protein‐coupled receptor 55 impairs glucose homeostasis during obesity by reducing insulin secretion and β‐cell turnover	68
Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status	68
Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes	67
Once‐weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis	67
Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open‐label, controlled trial	67
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease	66
Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin	66
Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study	65

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III	63
Efficacy and safety of diacerein monotherapy in adults with obesity: A randomized, double‐blind, placebo‐controlled trial	62
Adaptive bolus calculators for people with type 1 diabetes: A systematic review	62
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump	62
Response to letter from Du et al. regarding article ‘Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’	62
Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry	52
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta‐analysis	50
Type 2 diabetes pharmacotherapy trends in high‐risk subgroups	49
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Coh	49
The effects of antihypertensive drugs on glucose metabolism	48
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial	48
Long‐term effects of metformin on offspring health: A review of current evidence and future directions	47
Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity	47
GLP‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity	46
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic	45
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial	45
Plasma fatty acid esters of hydroxy fatty acids and surrogate fatty acid esters of hydroxy fatty acids hydrolysis activity in children with or without obesity and in adults with or without coronary ar	44
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c	43
Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes	43